St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 3, 2004, Pages 191-197

  Wang, Lian Sheng ^b   Zhou, Gan ^b   Zhu, Bing ^b   Wu, Jun ^b   Wang, Jian Gang ^b   Abd El Aty, A M ^b   Li, Tong ^b   Liu, Jie ^b   Yang, Tian Lun ^b   Wang, Dan ^b   Zhong, Xiang Yang ^b   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; OMEPRAZOLE; OMEPRAZOLE SULFONE; PLACEBO;

AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CATALYSIS; CATALYST; CONTROLLED STUDY; DRUG HYDROXYLATION; GENOTYPE; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERICUM PERFORATUM; MALE; MEDICINAL PLANT; NORMAL HUMAN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RADIATION DETECTION; RANDOMIZATION; SULFOXIDATION; ULTRAVIOLET RADIATION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYLATION; HYPERICUM; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PLANT EXTRACTS; SULFOXIDES;

EID: 12144289727     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.09.014     Document Type: Article

References (26)

1. Wallmark B., Sachs G., Mardh S., Fellenius E. Inhibition of gastric (H+ + K+)-ATPase by the substituted benzimidazole, picoprazole. Biochim Biophys Acta. 728:1983;31-38.
2. McTavish D., Buckley M.M., Heel R.C. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs. 42:1991;138-170.
3. Chiba K., Kobayashi K., Manabe K., Tani M., Kamataki T., Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther. 266:1993;52-59.
4. Karam W.G., Goldstein J.A., Lasker J.M., Ghanayem B.I. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 24:1996;1081-1087.
5. Chang M., Tybring G., Dahl M.-L., Gotharson E., Sagar M., Seensalu R., et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol. 39:1995;511-518.
6. Bottiger Y., Tybring G., Gotharson E., Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther. 62:1997;384-391.
7. Tassaneeyakul W., Vannaprasaht S., Yamazoe Y. Formation of omeprazole sulfone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br J Clin Pharmacol. 49:2000;139-144.
8. He N., Huang S.L., Zhu R.H., Tan Z.R., Liu J., Zhu B., et al. Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent. Xenobiotica. 33:2003;211-221.
9. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 269:1994;15419-15422.
10. Brosen K., de Morais S.M., Meyer U.A., Goldstein J.A. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics. 5:1995;312-317.
11. Desta Z., Zhao X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 41:2002;913-958.
12. Furuta T., Shirai N., Takashima M., Xiao F., Hanai H., Nakagawa K., et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics. 11:2001;341-348.
13. Wentworth J.M., Agostini M., Love J., Schwabe J.W., Chatterjee V.K. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol. 166:2000;R11-16.
14. Kasper S. Hypericum perforatum - a review of clinical studies. Pharmacopsychiatry. 34:(Suppl 1):2001;S51-55.
15. Henderson L., Yue Q.Y., Bergquist C., Gerden B., Arlett P. St John's wort (Hypericum perforatum) drug interactions and clinical outcomes. Br J Clin Pharmacol. 54:2002;349-356.
16. Durr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., et al. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 68:2000;598-604.
17. Roby C.A., Anderson G.D., Kantor E., Dryer D.A., Burstein A.H. St John's wort effect on CYP3A4 activity. Clin Pharmacol Ther. 67:2000;451-457.
18. Gonzalez H.M., Romero E.M., de J. Chavez T., Peregrina A.A., Quezada V., Hoyo-Vadillo C. Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 25:2002;459-465.
19. Ruschitzka F., Meier P.J., Turina M., Luscher T.F., Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet. 355:2000;548-549.
20. Breidenbach T., Kliem V., Burg M., Radermacher J., Hoffmann M.W., Klempnauer J. Profound drop in cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum). [letter] Transplantation. 69:2000;2229-2230.
21. Andersson T., Regardh C.G., Lou Y.C., Zhang Y., Dahl M.L., Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics. 2:1992;25-31.
22. Bertilsson L., Tybring G., Widen J., Chang M., Tomson T. Carbamazepine treatment induces the CYP3A4 catalyzed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol. 44:1997;186-189.
23. Shu Y., Wang L.S., Xiao W.M., Wang W., Huang S.L., Zhou H.H. Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone. Acta Pharmacol Sin. 21:2000;753-758.
24. Piscitelli S.C., Burstein A.H., Chaitt D., Alfaro R.M., Fallon J. Indinavir concentrations and St John's wort. Lancet. 355:2000;547-548.
25. Henderson L., Yue Q.Y., Bergquist C., Gerden B., Arlett P. St John's wort (Hypericum perforatum) drug interactions and clinical outcomes. Br J Clin Pharmacol. 54:2002;349-356.
26. Schwarz U.I., Buschel B., Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol. 55:2003;112-113.